本文關(guān)鍵詞： 失血性休克 中醫(yī)藥 系統(tǒng)評價 meta分析　出處：《大連醫(yī)科大學》2016年碩士論文　論文類型：學位論文

【摘要】：背景在中國中醫(yī)藥作為輔助療法已經(jīng)被廣泛應(yīng)用于失血性休克患者的治療中,大量的隨機對照試驗已經(jīng)對其療效進行了研究。目的對中醫(yī)藥(Traditional Chinese Medicine,TCM)聯(lián)合西醫(yī)常規(guī)療法(Conventional Therapy)治療失血性休克(Hemorrhagic Shock,HS)患者的有效性和安全性進行薈萃分析(Meta-analysis)。為將來中醫(yī)藥治療失血性休克的臨床推廣提供可靠的循證證據(jù)。方法用計算機對中國生物醫(yī)學文獻數(shù)據(jù)庫(China biomedical database web,CBM)、中國學術(shù)期刊全文數(shù)據(jù)庫(China national knowledge infrastructure databases,CNKI)、美國國立圖書館因特網(wǎng)檢索系統(tǒng)(Pub Med)、科學指引數(shù)據(jù)庫(Science Direct database)、荷蘭醫(yī)學文摘(EMBASE)、考克蘭圖書館(Cochrane Library)、萬方(Wang Fang data)、維普(VIP)等數(shù)據(jù)庫進行全面的檢索,檢索的起始時間為數(shù)據(jù)庫的建立時間,截止時間為2015年12月。符合中醫(yī)藥聯(lián)合常規(guī)西醫(yī)治療與單獨使用西醫(yī)常規(guī)治療失血性休克相比較的臨床隨機對照試驗(randomized clinical trials,RTCs)將會被納入,由2名評價員根據(jù)Cochrane系統(tǒng)評價手冊5.1.0版本對納入研究的偏倚風險以及文獻質(zhì)量獨立進行評價,并對納入研究的詳細信息進行提取。利用Rev Man5.2軟件對納入文獻的主要終點指標及次要終點指標進行合并統(tǒng)計分析,利用風險比(risk ratio,RR)、均數(shù)差(mean difference,MD)以及95%可信區(qū)間(95%CI)對效應(yīng)值進行評估,利用STATA 12.0軟件對發(fā)表偏倚進行評估。結(jié)果共有15篇隨機對照試驗符合我們的標準被納入,共包含了1076名受試者,且均為中文發(fā)表。本次的Meta分析結(jié)果顯示:(1)在降低死亡率層面,中醫(yī)藥聯(lián)合西醫(yī)常規(guī)治療治療失血性休克的療效要優(yōu)于單純西醫(yī)常規(guī)治療(RR=0.24,95%CI:0.13-0.46,P0.0001);(2)在減少多器官功能障礙綜合征(multiple organ dysfunction syndrome,MODS)的發(fā)生率方面,中醫(yī)藥聯(lián)合西醫(yī)常規(guī)治療失血性休克要優(yōu)于單純的西醫(yī)常規(guī)治療(RR=0.47,95%CI:0.34-0.66,P0.00001);(3)在增強心功能,穩(wěn)定心率方面,聯(lián)合治療組具有明顯優(yōu)勢(MD=-7.6,95%CI:-9.17—-6.02,P0.00001);(4)失血性休克復(fù)蘇時期,聯(lián)合治療組在升壓、穩(wěn)壓方面要優(yōu)于單純西醫(yī)常規(guī)治療(MD=8.83,95%CI:6.82-10.84,P0.00001);(5)在改善腎臟血流灌注、增加尿量輸出方面,聯(lián)合治療組優(yōu)于單純西醫(yī)常規(guī)治療(MD=7.26,95%CI:5.00-9.53,P0.00001)。用STATA 12.0軟件檢測發(fā)表偏倚時,漏斗圖和Egger檢驗結(jié)果提示各研究間沒有潛在發(fā)表偏倚。所有納入的研究都未對不良反應(yīng)進行報道。結(jié)論中醫(yī)藥聯(lián)合西醫(yī)常規(guī)治療失血性休克比單純的西醫(yī)常規(guī)治療更具優(yōu)勢。但是,中醫(yī)藥治療失血性休克的機制目前尚不清楚,未來需要進行更多的動物實驗和臨床試驗來探索其具體機制。此外,本次meta分析也存在一定的局限性,一方面是納入文獻的方法學質(zhì)量問題:納入文獻都說明是隨機分組,但是大部分研究都沒有詳細描述隨機分配序列的產(chǎn)生方法,而且都沒有描述隨機序列的隱藏方法,所有試驗都沒有說明盲法的具體實施過程;另一方面聯(lián)合治療組中使用干預(yù)藥物的組方(單品、復(fù)方或注射液)、劑量和療程的差異也是導(dǎo)致我們不能得出一個明確結(jié)論的原因。未來需要更多的經(jīng)過嚴格設(shè)計的、多中心的、大規(guī)模的前瞻性隨機對照試驗來增加中醫(yī)藥治療HS臨床療效的可靠性與確切性。
[Abstract]:The background as adjuvant therapy has been widely used in the treatment of hemorrhagic shock patients in China Chinese medicine, a large number of randomized controlled trials have been carried out to study the effect of traditional Chinese medicine. (Traditional Chinese, Medicine, TCM) combined with conventional western medicine therapy (Conventional Therapy) in the treatment of hemorrhagic shock (Hemorrhagic, Shock, HS) effective the safety of patients for meta-analysis (Meta-analysis). To provide reliable evidence for clinical future promotion of Chinese medicine in the treatment of hemorrhagic shock. The database method for computer Chinese biological medical literature (China biomedical database web, CBM), Chinese Academic Journal Full-text Database (China National Knowledge infrastructure databases, CNKI). The National Library of Internet retrieval system (Pub Med), scientific guidelines (Science Direct database) database, Holland Medical Abstracts (EMB ASE), the Cochrane Library (Cochrane Library), Wanfang (Wang Fang data), VIP database (VIP) to conduct a comprehensive search, the starting time for the establishment of the database retrieval time, the deadline for December 2015. In line with the clinical randomized controlled trials of traditional Chinese medicine combined with conventional Western Medicine alone and conventional western medicine treatment of hemorrhagic shock compared to the (randomized clinical trials, RTCs) will be included, by 2 reviewers according to the manual evaluation of Cochrane system 5.1.0 version of the risk of bias of included studies and literature quality in independent evaluation, and the detailed information included in the study were extracted. Combined with statistical analysis of the main indicators of indicators included in the literature and the secondary end point end point using Rev Man5.2 software, using the risk ratio (risk ratio RR), mean difference (mean difference, MD) and 95% confidence intervals (95%CI) to evaluate effect value, Use STATA 12 software to assess the publication bias. Results a total of 15 randomized controlled trials met our criteria were enrolled, included 1076 subjects, which were published Chinese. The results of Meta analysis showed that the (1) in reducing mortality level, is superior to the conventional western medicine treatment of traditional Chinese medicine combined with conventional Western medicine therapy efficacy in the treatment of hemorrhagic shock (RR=0.24,95%CI:0.13-0.46, P0.0001); (2) reduction in multiple organ dysfunction syndrome (MODS multiple organ dysfunction syndrome) the incidence of traditional Chinese medicine, combined with conventional western medicine in the treatment of hemorrhagic shock is better than pure Western conventional treatment (RR=0.47,95%CI:0.34-0.66, P0.00001); (3) to improve cardiac function and stabilize heart rate, the combined treatment group has obvious advantages (MD=-7.6,95%CI:-9.17, -6.02, P0.00001); (4) hemorrhagic shock and resuscitation period, the combined treatment group in boost, Regulator is superior to the conventional western medicine treatment (MD=8.83,95%CI:6.82-10.84, P0.00001); (5) in renal perfusion, increase urine output, the combined treatment group is better than routine western medicine (MD=7.26,95%CI:5.00-9.53, P0.00001). Using STATA 12 software to detect publication bias, funnel plots and Egger test results indicate that the study did not the potential publication bias. All included studies were not adverse reactions were reported. Conclusion the traditional Chinese medicine combined with conventional western medicine in the treatment of hemorrhagic shock has more advantage than simple routine western medicine. However, traditional Chinese medicine treatment mechanism of hemorrhagic shock is not clear, the future need to explore the mechanism of animal experiment more and in clinical trials. In addition, the meta analysis has some limitations, one is the methodological quality of included literature shows that: It is randomized, but most of them are not a detailed description of the random sequence method, and can not describe the hidden method of random sequence, all the tests did not explain the specific implementation of the blind method; the use of prescription drug intervention combined treatment group (on the other hand, in a single product, compound or injection), and dose difference the course is also the cause we cannot draw a definite conclusion. The future need for more rigorous design, multi center, large prospective randomized placebo-controlled trials to increase the reliability of the clinical curative effect of the TCM treatment of HS with certainty.

【學位授予單位】：大連醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R278

【參考文獻】

相關(guān)期刊論文 前10條

1 盧志強;張艷軍;莊朋偉;張金保;周會芳;陳卓;孫萌;徐利滿;;附子對急性心力衰竭大鼠血流動力學影響及其機制研究[J];中草藥;2015年21期

2 潘金波;陳曄;;休克的中醫(yī)辨證論治[J];中國中西醫(yī)結(jié)合急救雜志;2015年05期

3 潘文;米俊;趙強;;參附注射液聯(lián)合多巴胺與多巴胺單用治療心源性休克60例療效觀察[J];中國中醫(yī)急癥;2015年09期

4 鄭悅亮;蔡文偉;周晟昂;許利明;閆廣照;許遠展;;參附注射液對“失血性休克-內(nèi)毒素”二次打擊急性肺損傷治療作用研究[J];中華中醫(yī)藥雜志;2015年08期

5 徐冰;趙剡;夏劍;;參附注射液對創(chuàng)傷失血性休克患者凝血功能和炎性因子的影響[J];海南醫(yī)學院學報;2015年02期

6 董桂銀;;大黃粉劑對創(chuàng)傷性休克后胃腸功能障礙并MODS患者kE及TNF-α水平的影響[J];重慶醫(yī)學;2014年25期

7 于曉文;杜鴻志;孫立;袁勝濤;;麥冬皂苷藥理作用研究進展[J];藥學進展;2014年04期

8 陳榮昌;孫桂波;張強;孫曉波;;附子及其復(fù)方中藥的藥理作用研究進展[J];中草藥;2014年06期

9 鄭志鵬;陳功雷;康德;洪加源;李昌;;益氣復(fù)脈聯(lián)合多巴胺在創(chuàng)傷失血性休克的應(yīng)用[J];內(nèi)科急危重癥雜志;2013年06期

10 路曉光;康新;戰(zhàn)麗彬;于健;楊榮利;范治偉;肖威強;李思瑤;梁正凱;余潔;于亮亮;;大黃附子湯對失血性休克急性肺損傷患者的保護作用[J];中華急診醫(yī)學雜志;2013年12期

，

本文編號：1504603